Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.320
+0.040 (0.93%)
At close: Nov 7, 2025, 4:00 PM EST
4.339
+0.019 (0.43%)
After-hours: Nov 7, 2025, 6:45 PM EST
Adverum Biotechnologies Revenue
Adverum Biotechnologies had revenue of $1.00M in the twelve months ending June 30, 2025. In the year 2024, Adverum Biotechnologies had annual revenue of $1.00M, down -72.22%.
Revenue (ttm)
$1.00M
Revenue Growth
-72.22%
P/S Ratio
90.34
Revenue / Employee
$6,452
Employees
155
Market Cap
90.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | -2.60M | -72.22% |
| Dec 31, 2023 | 3.60M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 7.50M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADVM News
- 14 days ago - Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM - Business Wire
- 15 days ago - Eli Lilly to buy gene therapy developer Adverum in about $262 million deal - Reuters
- 15 days ago - Lilly to Acquire Adverum Biotechnologies - PRNewsWire
- 6 weeks ago - Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 6 months ago - Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewsWire